Pilot Study of Physostigmine-Enhanced Opioid Analgesia

• Status: Completed
• Trial end date: 2011-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators hypothesize that the administration of physostigmine in the postoperative period after nephrectomy reduces opioid consumption.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Medical University of Graz
• Treatments: Physostigmine

Criteria

Inclusion Criteria:

• At least 18 years old

• At least 50 kg

• Suitable for PCA

• ASA 1-3

Exclusion Criteria:

• Bronchial asthma/severe or exacerbated COPD

• Iritis

• Stenoses/spasms of intestine, urinary tract, biliary tract

• Closed traumatic brain injury

• Severely reduced left ventricular function (EF<30%)

• Recent myocardial infarction

• Recent stroke

• Known allergy or hypersensitivity or contraindications against hydromorphone, physostigmine

• History of alcohol or drug abuse

• Patients enrolled in another study

• Women of childbearing age without a negative pregnancy test